Why Early Market Access Planning Is Crucial In CGT Commercial Strategy

Cell and gene therapies (CGTs) hold great promise for patients with serious diseases, but bringing these treatments to market and ensuring patient access is a complex process. To navigate this landscape successfully, experts recommend that CGT manufacturers develop a market access strategy early on in the development process.

One key aspect of this strategy is designing a limited distribution network (LDN) that takes into account factors such as site readiness, geographic spread, and proximity to patients. It is important to address product-specific distribution needs and consider the impact of the network on patient referral patterns. Additionally, offering support services for patients who need to travel for treatment can enhance their experience.

Engaging with payers early in the process is crucial to ensure coverage and reimbursement align with the planned network. Payers need to be educated about the unique challenges of CGTs, including their high upfront costs and long-term durability. CGT manufacturers should play a role in shaping payment contracts and demonstrating the unique value of their therapies through tailored pre-approval information exchange.

Partnering with a commercialization specialist can be beneficial for CGT manufacturers in developing effective market access strategies. The right partner can provide expertise in navigating the complexities of payer communication, site engagement, and distribution network design.

Discover how developing a market access strategy early on, addressing challenges such as distribution network design and payer communication, and partnering with experts can help CGT manufacturers increase the chances of successful commercialization and patient access to these life-saving therapies.